GSP as an Novel Indicator for Residual Liver Function in Patients With Fatty Liver

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

210

Participants

Timeline

Start Date

July 5, 2007

Primary Completion Date

August 12, 2007

Study Completion Date

October 31, 2018

Conditions
Galactose Single Point (GSP), Residual Liver Function
Interventions
DRUG

Drug: G.S.P. Solution 400 mg/ml I.V. 1.25 ml/kg BW G.S.P. solution after fasting for 6 hours.

All Listed Sponsors
collaborator

Cardinal Tien Hospital

OTHER

collaborator

Tri-Service General Hospital

OTHER

lead

National Defense Medical Center, Taiwan

OTHER

NCT04546022 - GSP as an Novel Indicator for Residual Liver Function in Patients With Fatty Liver | Biotech Hunter | Biotech Hunter